A rise in the concurrent use of ketogenic diets and SGLT-2 inhibitors to control weight in diabetic patients is due to the increased use of SGLT-2 inhibitors in the management of diabetes [28]. The gene discussed is SLC5A2; the disease is diabetes mellitus.